Obseva Announces Appointment of Stephanie Brown to its Board of Directors
November 22, 2021 01:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland November 22, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Announces Third Quarter 2021 Financial Results and Business Update
November 04, 2021 02:00 ET
|
ObsEva SA
-Linzagolix for uterine fibroids: Pending regulatory approval in the US and Europe with commercial planning efforts underway- -Linzagolix for endometriosis: Readout from Phase 3 EDELWEISS 3...
ObsEva Announces Management Change
October 29, 2021 16:30 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – October 29, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 Scientific Congress & Expo
October 20, 2021 01:00 ET
|
ObsEva SA
-Final results from pilot study of linzagolix for the treatment of severe adenomyosis to be presented in a second poster - Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss...
ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & Expo
October 19, 2021 01:00 ET
|
ObsEva SA
–Presentation of Phase 3 clinical data on linzagolix for the treatment of uterine fibroids and final results from a pilot study of linzagolix for the treatment of severe adenomyosis– GENEVA,...
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
October 13, 2021 01:00 ET
|
ObsEva SA
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix -Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of...
ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer
September 30, 2021 01:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – September 30, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids
September 15, 2021 01:00 ET
|
ObsEva SA
-If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids- -NDA submission includes positive data...
ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 01:00 ET
|
ObsEva SA
GENEVA, Switzerland September 7, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today...
ObsEva Announces Second Quarter 2021 Financial Results and Business Update
August 05, 2021 01:00 ET
|
ObsEva SA
-Linzagolix (Yselty®) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing approval recommendation anticipated in Q4:21- -Linzagolix for endometriosis:...